Article thumbnail

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates

By Ezra Mulugeta, Elisabet Londos, Oskar Hansson, Clive Ballard, Ragnhild Skogseth, Lennart Minthon, Kaj Blennow, Henrik Zetterberg and Dag Aarsland


We measured cerebrospinal fluid (CSF) levels of the soluble isoforms of amyloid precursor protein (APP; sAPPα sAPPβ) and other CSF biomarkers in 107 patients with Alzheimer's disease (AD), dementia with Lewy body dementia (DLB), Parkinson's disease dementia (PDD), and normal controls (NC) using commercial kits. DLB and PDD were combined in a Lewy body dementia group (LBD). No differences were observed in sAPPα and sAPPβ levels between the groups. Significant correlations were observed between sAPPα and sAPPβ and between sAPPβ and Mini-Mental State Examination scores in the total group analysis as well as when LBD and AD groups were analyzed separately. sAPPα and sAPPβ levels correlated with Aβ38, Aβ40, Aβ42, and Tau in the LBD group. In AD, sAPPα correlated with p-Tau and sAPPβ with Aβ40. The differential association between sAPPα and sAPPβ with Aβ and Tau species between LBD and AD groups suggests a possible relationship with the underlying pathologies in LBD and AD

Topics: Clinical Study
Publisher: SAGE-Hindawi Access to Research
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2010). A .G a b e l l e ,S .R o c h e ,C .G ´ eny et al., “Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid,”
  2. (2011). Alzheimer’s disease,”
  3. (2011). APP processing in Alzheimer’s disease,”
  4. (1997). Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives,”
  5. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease,”
  6. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices
  7. (2011). CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies,”
  8. (2003). Dementia associated with Parkinson’s disease,”
  9. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology,
  10. Elevated cerebrospinal fluid BACE1 activity in incipient alzheimer disease,”
  11. (2007). Fluctuations of CSF amyloid-β levels: implications for a diagnostic and therapeutic biomarker,”
  12. (2008). Frequency andcaseidentificationofdementiawithLewybodiesusingthe revised consensus criteria,”
  13. (2009). Functional roles of amyloid-β protein precursor and amyloid-β peptides: evidence from experimental studies,”
  14. (2004). M a t t s o n ,“ P a t h w a y st o w a r d sa n da w a yf r o mA l z h e i m e r ’ s disease,”
  15. (2009). Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial,”
  16. (1997). Metabotropic glutamate receptor subtype mGlur1α stimulates the secretion of the amyloid β-protein precursor ectodomain,”
  17. (1992). N i t s c h ,B .E .S l a c k ,R .J .W u r t m a n ,a n dJ .H .G r o w d o n , “Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors,”
  18. (1993). N i t s c h ,S .A .F a r b e r ,J .H .G r o w d o n ,a n dR .J .W u r t m a n , “Release of amyloid β-protein precursor derivatives by electricaldepolarizationofrathippocampalslices,”Proceedingsofthe
  19. (2009). Parkinson’s disease dementia and dementia with Lewy bodies: different aspects of one entity,”
  20. (1995). Regulated secretion of β-amyloid precursor protein in rat brain,”
  21. (2010). regulates transthyretin and Klotho gene expression without rescuing the essential function of APP,”
  22. (2003). Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory,”
  23. (2003). Sj¨ ogren et al., “Measurement of α-a n dβ-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients,”
  24. (2010). Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: a multicenter study,”
  25. (2011). Striatal Aβ peptide deposition mirrors dementia and differentiates
  26. (2011). Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic tau mutant,”
  27. (2004). The informant questionnaire on cognitive decline in the elderly (IQCODE): a review,”